News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|June 10, 2024

Natural History of Spinal Muscular Atrophy

Author(s)Lauren Elman, MD, Arun S. Varadhachary, MD, PhD , Thomas Crawford, MD

Panelists examine the natural history of spinal muscular atrophy (SMA), assessing the characteristic indicators of motor function deterioration and the loss of ambulatory abilities as patients advance in age.

Episodes in this series

Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"

EP. 1 Clinical Features and Phenotypes of Spinal Muscular Atrophy

Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"

EP. 2 Natural History of Spinal Muscular Atrophy

Video 3 - 5 KOLs are featured in "Presentation of Adult Spinal Muscular Atrophy in Clinics"

EP. 3 Presentation of Adult Spinal Muscular Atrophy in Clinics

Video 3 - 5 KOLs are featured in "Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics"

EP. 4 Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics

Video 5 - 5 KOLs are featured in "Key Players in Transitioning Patients with SMA from Pediatric Care to Adult Health Care"

EP. 5 Key Players in Transitioning Patients with SMA from Pediatric Care to Adult Health Care

Video 5 - 5 KOLs are featured in "Managing Clinical Stability in Adults Spinal Muscular Atrophy Patients"

EP. 6 Managing Clinical Stability in Adults Spinal Muscular Atrophy Patients

5 KOLs are featured in this series.

EP. 7 Treatments Approved for Treatment of Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 8 Factors Guiding Treatment Selection in Adult Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 9 Switching Treatments in Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 10 Determining Treatment Success in Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 11 Counseling Patients About Treatment Outcomes in Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 12 Real-World Data and Stability with Nusinersen in Adult Patients with Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 13 Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 14 Transition of Care in Young Adults With Spinal Muscular Atrophy

5 KOLs are featured in this series.

EP. 15 Recommendations for Clinicians Taking Care of Patients with SMA

What do we know about the natural history of SMA?
Discuss decline in motor function and loss of ambulation over time in adults.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Excessive Daytime Sleepiness Associated With Cognitive Deficits and Abnormal Brain Network Topology in Obstructive Sleep Apnea

ByIsabella Ciccone, MPH

September 8th 2026

Del-Desiran Fails to Meet Primary Endpoint in Phase 3 HARBOR Trial of Myotonic Dystrophy 1

ByLouie Pasculli

September 8th 2026

Investigational Zorevunersen Linked to Adaptive Gains in Dravet Syndrome

September 8th 2026

Tirofiban Plus Aspirin Fails to Reduce Early Neurological Deterioration in BAD-Related Stroke

ByLouie Pasculli

September 8th 2026

Excessive Daytime Sleepiness Affects Over 70% of Brazilian Adolescents, Tied to Depression, Smartphone Addiction, Diet

ByIsabella Ciccone, MPH

September 7th 2026

Latest CME

2026 Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

2026 Carolina Neuromuscular Disease Summit

September 19-20, 2026

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

In-Person Event

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Investigational Zorevunersen Linked to Adaptive Gains in Dravet Syndrome

Del-Desiran Fails to Meet Primary Endpoint in Phase 3 HARBOR Trial of Myotonic Dystrophy 1

Tirofiban Plus Aspirin Fails to Reduce Early Neurological Deterioration in BAD-Related Stroke

National Analysis Reveals Certified Headache Specialists Absent From More Than 90% of US Counties

Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia